Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

Summary

This is a pharmacokinetic study (PK Study) to better understand empagliflozin dosing in pediatric Duchenne muscular dystrophy patients. Empagliflozin is currently used off-label in this population due to the mortality benefits seen in adult cardiomyopathy and heart failure. Investigators will perform PK studies in DMD patients of various ages and weights to better understand the PK profile (absorption, distribution, metabolism, excretion) and dosing to better treat Duchenne cardiomyopathy.

Eligibility

Inclusion Criteria:

* Clinical phenotype of DMD confirmed with muscle biopsy or genotype
* Presence of late gadolinium enhancement (LGE) imaging by CMR
* Either normal or mildly depressed systolic function (LVEF\>40%)
* ≥8 years old and ≤18 years old

Exclusion Criteria:

* Current investigational therapy that may affect cardiovascular function

  * Additional genetic or congenital abnormality that may affect cardiovascular function or progression
  * Contraindication to or inability to undergo CMR
  * Symptomatic heart failure
  * History of ketoacidosis or hypersensitivity to SGLT2i therapy
  * Type 1 diabetes
  * Renal disease or history of frequent urinary tract infections or genitourinary skin infections

Conditions2

Interventions2

Locations1 site

Find trials near these locations

Related trials

• Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors — McGill University
• Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study — Kyungsub Song
• The Use of Advanced Imaging in HFpEF — Sheffield Teaching Hospitals NHS Foundation Trust
• Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD — Cardenal Herrera University
• Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients — Kafrelsheikh University
• Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes — Chong Kun Dang Pharmaceutical
• Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention — Samsung Medical Center
• SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study — Kiyuk Chang

Browse More Trials